P Lx Pharma Inc. PLXP
We take great care to ensure that the data presented and summarized in this overview for PLx Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PLXP
View all-
Eidelman Virant Capital27KShares$00.01% of portfolio
-
O'Brien Greene & Co. Inc Media, PA27KShares$00.0% of portfolio
-
Exane Derivatives6.58KShares$00.01% of portfolio
-
Financial Gravity Asset Management, Inc.1.05KShares$00.0% of portfolio
-
Financial Gravity Companies, Inc. Lakeway, TX1.05KShares$00.0% of portfolio
-
Tucker Asset Management LLC Littleton, CO25Shares$00.0% of portfolio
Latest Institutional Activity in PLXP
Top Purchases
Top Sells
About PLXP
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Insider Transactions at PLXP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2022
|
Rita M O'Connor Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
13,700
+21.26%
|
$41,100
$3.66 P/Share
|
|
Mar 15
2022
|
Natasha Giordano Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,100
+44.15%
|
$12,300
$3.65 P/Share
|
|
Jun 14
2021
|
Michael J Valentino Executive Chairman |
BUY
Open market or private purchase
|
Direct |
8,000
+0.18%
|
$96,000
$12.47 P/Share
|
|
Mar 05
2021
|
Michael J Valentino Executive Chairman |
BUY
Open market or private purchase
|
Direct |
25,000
+4.89%
|
$200,000
$8.0 P/Share
|
|
Dec 14
2020
|
John Hadden Director |
BUY
Open market or private purchase
|
Direct |
1,000
+12.6%
|
$5,000
$5.46 P/Share
|
|
Nov 25
2020
|
John Hadden Director |
BUY
Open market or private purchase
|
Direct |
500
+15.67%
|
$2,500
$5.48 P/Share
|
|
Nov 18
2020
|
Michael J Valentino Executive Chairman |
BUY
Open market or private purchase
|
Direct |
264,900
+36.46%
|
$794,700
$3.79 P/Share
|
|
Dec 27
2018
|
Park West Asset Management LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
397,495
+21.25%
|
$397,495
$1.0 P/Share
|